Cipla shares broke out above ₹1,580–₹1,590 on strong volumes, with technical indicators signaling further gains.

Pharma companies are separating consumer healthcare businesses to drive growth, facing challenges in a competitive market.

If the deal works out, it would be the largest in the Indian pharma sector, analysts said. Cipla's shares jumped as much as 4.1% after the results and were up 1.9%, as of 3:20 p.m. IST.

Nomura’s June 2025 analysis shows Indian pharma majors like Sun Pharma, Dr. Reddy’s, Cipla, Lupin, and Zydus posting strong ...

The Nifty Pharma Index gained more than 1% amid a weak Indian stock market on a day when the benchmark Nifty 50 Index dipped ...

India's Torrent Pharmaceuticals is in talks with private equity funds CVC Capital Partners and Bain Capital to raise up to $1.5 billion to bid for India's Cipla, according to three sources with ...

Indian pharmaceutical giants, including Sun Pharma and Cipla, seize the opportunity to develop affordable versions of Novo Nordisk's Wegovy weight-loss treatment. With patents set to expire by ...

Dr Reddy's Laboratories (DRL), Cipla, Sun Pharma, and Mankind Pharma, among others, are laying the groundwork for Day 1 ...

Zee Business analysts Ansh Jogendra Bhilwar and Pooja Tripathi have shared a number of calls for trading and investing today, ...

The market may continue to consolidate with a negative bias in the upcoming sessions. Below are some short-term trading ideas to consider.

Cipla's shares closed 2.03% higher on Friday after the results. They have risen nearly 17% in the September quarter, outpacing a 12% rise in the Nifty Pharma index (.NIPHARM).